health

The clearest shift this week is the arrival of the first published human safety and efficacy data on faecal microbiota transplantation (FMT) in Parkinson's — a procedure that replaces the patient's gut bacterial community with a donor's. The study in npj Parkinson's Disease found it safe and produced efficacy signals in PD patients. The gut-brain connection in Parkinson's has moved from hypothesis to clinical target with human results behind it. FMT is not standard of care and access outside specialist trials remains very limited, but if you carry significant gastrointestinal symptoms alongside motor fluctuations, asking whether a gut microbiome trial is enrolling near you is now a reasonable clinical question.

A practical fix for drooling that many neurologists haven't tried

Drooling (sialorrhea) affects a large share of people with Parkinson's and has had few satisfying treatment options. A case series in Movement Disorders reports marked improvement with safinamide — an MAO-B inhibitor already used for motor fluctuations — suggesting a dual benefit that many patients may not be receiving. Case series data is preliminary, but if drooling is a daily burden and you are on or considering safinamide, this is worth raising at the next appointment.

Young plasma: striking early signal, very early stage

A small preprint study reports that infusions of plasma from young donors improved motor scores and daily function in PD patients. The signal is notable; the evidence is not. This is preliminary human data, uncontrolled, and plasma therapy carries real risks and ethical complexities around sourcing. File it as a watch item — not something to seek out privately — and expect scrutiny before guidance follows.

Building a personal prognosis: levodopa response and alpha-synuclein now speak together

Two papers deepen the precision-prognosis picture. A large Annals of Neurology study establishes that levodopa responsiveness — how well a patient responds to the main Parkinson's drug — is not just a therapeutic variable but a diagnostic and prognostic signal that correlates with underlying brain pathology and helps distinguish PD from related conditions like MSA and PSP. Separately, a medRxiv preprint shows that the alpha-synuclein seed amplification assay (a blood or CSF test detecting misfolded protein) can identify which carriers of the LRRK2 gene variant already have active PD pathology — relevant for anyone in a genetic monitoring program. Together with last week's 15-year cognitive decline dataset, a toolkit for individual-level prognosis is assembling that clinicians will increasingly be able to deploy in practice.

Mixed pathologies: why your Parkinson's isn't like anyone else's

A major international MDS scientific committee review confirms that most people with PD carry additional brain pathologies alongside alpha-synuclein — Alzheimer's-type changes, vascular damage, TDP-43 protein accumulation. This is expert consensus, not new trial data, but it is an important frame. Disease heterogeneity is not random variation — it reflects real underlying biological differences that explain why two people with the same diagnosis can have very different trajectories. It also underlines why blanket trial results may not translate uniformly and why personalised, biomarker-informed care is the direction the field is heading.

Pipeline: a setback and two finishes

Denali Therapeutics abandoned a Parkinson's drug program this week — a meaningful pipeline loss. On the constructive side, the Celeste light therapy pivotal trial has completed enrollment; results from this drug-free device approach are now expected. And the Phase 3 solengepras trial — a non-dopaminergic mechanism, meaning it works through a pathway other than replacing lost dopamine — is fully enrolled, putting results within a foreseeable horizon.

Free genetic testing goes global

PD GENEration, the free Parkinson's genetic testing program previously centered in the US, is expanding internationally with results linked to open trial opportunities. If you have not been tested and want to understand your genetic variant status — or access mutation-specific trials — this program is now worth checking wherever you are.